PCSK9: From discovery to therapeutic applications

Archives of Cardiovascular Diseases

Volumn 107, Issue 1, 2014, Pages 58-66

  Farnier, Michel ^a  

^a Point Medical   (France)

Author keywords

Familial hypercholesterolaemia; LDL cholesterol; LDL receptor; Monoclonal antibodies; Proprotein convertase subtilisin kexin type 9 (PCSK9)

Indexed keywords

ALIROCUMAB; BOCOCIZUMAB; EVOLOCUMAB; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD LEVEL; CHOLESTEROL METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL; MONOTHERAPY; NONHUMAN;

ANTICORPS MONOCLONAUX; FAMILIAL HYPERCHOLESTEROLAEMIA; HYPERCHOLESTÉROLÉMIE FAMILIALE; LDL CHOLESTEROL; LDL-CHOLESTÉROL; LDL-RECEPTOR; MONOCLONAL ANTIBODIES; PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9); RÉCEPTEUR DES LDL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; PROPROTEIN CONVERTASES; PROTEIN KINASE INHIBITORS; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84895075938     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2013.10.007     Document Type: Review

References (49)

1. M. Marduel, A. Carrie, and A. Sassolas et al. Molecular spectrum of autosomal dominant hypercholesterolemia in France Hum Mutat 31 2010 E1811 E1824
2. M. Farnier The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications Am J Cardiovasc Drugs 11 2011 145 152
3. D. Rhainds, B.J. Arsenault, and J.C. Tardif PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials Clin Lipid 7 2012 621 640
4. N.G. Seidah PCSK9 as a therapeutic target of dyslipidemia Expert Opin Ther Targets 13 2009 19 28
5. N.G. Seidah, and A. Prat The biology and therapeutic targeting of the proprotein convertases Nat Rev Drug Discov 11 2012 367 383
6. N.G. Seidah, S. Benjannet, and L. Wickham et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation Proc Natl Acad Sci U S A 100 2003 928 933
7. M. Abifadel, M. Varret, and J.P. Rabes et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156
8. G. Tibolla, G.D. Norata, and R. Artali et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition Nutr Metab Cardiovasc Dis 21 2011 835 843
9. J. Davignon, G. Dubuc, and N.G. Seidah The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis Curr Atheroscler Rep 12 2010 308 315
10. J. Cohen, A. Pertsemlidis, and I.K. Kotowski et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 Nat Genet 37 2005 161 165
11. J.C. Cohen, E. Boerwinkle, and T.H. Mosley Jr. et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
12. M. Benn, B.G. Nordestgaard, and P. Grande et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses J Am Coll Cardiol 55 2010 2833 2842
13. C. Baigent, A. Keech, and P.M. Kearney et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
14. B.A. Ference, W. Yoo, and I. Alesh et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
15. J. Mayne, T. Dewpura, and A. Raymond et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture Clin Chem 57 2011 1415 1423
16. G. Lambert, B. Sjouke, and B. Choque et al. The PCSK9 decade J Lipid Res 53 2012 2515 2524
17. N.G. Seidah, M.S. Sadr, and M. Chretien et al. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions J Biol Chem 288 2013 21473 21481
18. S. Rashid, D.E. Curtis, and R. Garuti et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 Proc Natl Acad Sci U S A 102 2005 5374 5379
19. P. Lo Surdo, M.J. Bottomley, and A. Calzetta et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH EMBO Rep 12 2011 1300 1305
20. H. Tavori, D. Fan, and J.L. Blakemore et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation Circulation 127 2013 2403 2413
21. A. Roubtsova, M.N. Munkonda, and Z. Awan et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue Arterioscler Thromb Vasc Biol 31 2011 785 791
22. E. Levy, A. Ben Djoudi Ouadda, and S. Spahis et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells Atherosclerosis 227 2013 297 306
23. M. Mbikay, F. Sirois, and J. Mayne et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities FEBS Lett 584 2010 701 706
24. Z. Zhao, Y. Tuakli-Wosornu, and T.A. Lagace et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523
25. X. Sun, R. Essalmani, and R. Day et al. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver Neoplasia 14 2012 1122 1131
26. M. Denis, J. Marcinkiewicz, and A. Zaid et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice Circulation 125 2012 894 901
27. R.H. Al-Mashhadi, C.B. Sorensen, and P.M. Kragh et al. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant Sci Transl Med 5 2013 166ra1
28. H.E. Careskey, R.A. Davis, and W.E. Alborn et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 J Lipid Res 49 2008 394 398
29. G. Welder, I. Zineh, and M.A. Pacanowski et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol J Lipid Res 51 2010 2714 2721
30. J.A. Hedrick Targeting PCSK9 for the treatment of hypercholesterolemia Curr Opin Investig Drugs 10 2009 938 946
31. A.J. Hooper, and J.R. Burnett Anti-PCSK9 therapies for the treatment of hypercholesterolemia Expert Opin Biol Ther 13 2013 429 435
32. B. Ason, S. Tep, and H.R. Davis Jr. et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9 J Lipid Res 52 2011 679 687
33. M. Frank-Kamenetsky, A. Grefhorst, and N.N. Anderson et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Proc Natl Acad Sci U S A 105 2008 11915 11920
34. K. Fitzgerald, M. Frank-Kamenetsky, and T. Mant et al. Phase I safety, pharmacokinetic, and pharmacodynamics results for ALN-PCS, a novel RNAi therapeutic for the treatment of hypercholesterolemia Arterioscler Thromb Vasc Biol 32 2012 A67 [abstract]
35. E.A. Stein, S. Mellis, and G.D. Yancopoulos et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
36. J.M. McKenney, M.J. Koren, and D.J. Kereiakes et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
37. E.M. Roth, J.M. McKenney, and C. Hanotin et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
38. E.A. Stein, D. Gipe, and J. Bergeron et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
39. C.S. Dias, A.J. Shaywitz, and S.M. Wasserman et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins J Am Coll Cardiol 60 2012 1888 1898
40. R.P. Giugliano, N.R. Desai, and P. Kohli et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
41. M.J. Koren, R. Scott, and J.B. Kim et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
42. F. Raal, R. Scott, and R. Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
43. D. Sullivan, A.G. Olsson, and R. Scott et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
44. A.H. Pijlman, R. Huijgen, and S.N. Verhagen et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands Atherosclerosis 209 2010 189 194
45. N.R. Desai, P. Kohli, and R.P. Giugliano et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-thrombolysis in myocardial infarction (TIMI) 57 trial Circulation 128 2013 962 969
46. E.A. Stein, N. Honarpour, and S.M. Wasserman et al. Effect of the PCSK9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2013 2113 2120
47. J. Chaparro-Riggers, H. Liang, and R.M. DeVay et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 J Biol Chem 287 2012 11090 11097
48. B. Gumbiner, C. Udata, and T. Joh et al. The effects of single dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin Circulation 126 2012 A13322 [abstract]
49. A.L. Catapano, and N. Papadopoulos The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway Atherosclerosis 228 2013 18 28